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Tumor recurrence: a poorly understood 
phenomenon
Typically, when a tumor is discovered, patients are 
treated with a combination of surgery, chemotherapy and 
radiotherapy, depending on the location and type of 
cancer. The goal of these treatments is to completely 
remove or destroy any cancerous cell growth. Often these 
treatments are met with apparent success, as indicated by 
shrinkage in tumor volume. Tumor reemergence is, 
however, frequent [1] but this phenomenon is poorly 
understood. It is not even clear whether one common 
factor underpins the ability of many different tumor types 
to reemerge after a remission period.
This general problem has led researchers to investigate 
possible explanations for tumor recurrence. One idea is 
that tumor heterogeneity is derived from a cell capable of 
generating many different cell types. This has led to the 
prediction that at least some tumors arise from a cell with 
stem-like properties. It is unclear, however, whether this 
would be a naturally occurring multipotent stem cell or a 
cell that acquires stem-like properties following 
mutational events, for example. Although the origin of 
these stem-like cells is contentious, the term cancer stem 
cell (CSCs) is often applied and will be used here. CSCs 
are currently a ‘hot’ topic because their potential 
properties are consistent with a tumor-initiating cell that 
might be able to regenerate the complexity of an entire 
tumor [2]. The obvious question, however, is how CSCs 
could survive genotoxic damage under conditions in 
which other tumor cells die. The answer to this question 
could be crucial for the development of new tumor 
therapeutics.
Subpopulations with increased apoptotic 
resistance
Understanding the mechanisms underpinning resistance 
to apoptosis following chemo- or radiotherapy has been 
prompted by the promise that this could lead to a new 
generation of therapeutic approaches. Several reports 
indicate that CSCs can pump out toxins through specific 
chemical efflux pathways [3]. These cells are often 
resistant to DNA damage and show greater DNA repair 
capacity than their non-stem-like counterparts [4]. New 
findings reported in BMC Cancer [5] reveal that altered 
cell cycle regulation could also have a role in apoptotic 
resistance in at least some CSCs.
Epithelial tumors are the most commonly diagnosed 
cancer type [6] and are therefore a high priority in terms 
of therapeutic development. Mackenzie and colleagues 
[5] address the problem by focusing on human head and 
neck squamous cell carcinomas (HNSCCs). HNSCCs are 
epithelial tumors with a high rate of tumor recurrence 
following initial treatment [7], making them a logical 
choice for investigation of apoptotic resistance mecha-
nisms. As in previous studies, subpopulations of cells 
with stem-like properties were isolated by fluorescence-
activated cell sorting (FACS), using the cell surface glyco-
protein CD44 as a marker. Assays comparing in vitro 
‘tumor sphere’ formation and clonogenicity demon strated 
that cells expressing high levels of CD44 (CD44high) with a 
highly compact, holoclone colony morphology have 
stem-like characteristics of CSCs.
Mackenzie and colleagues [5] show that CD44high cells 
are less sensitive to several chemical apoptosis-inducing 
agents than are CD44low cells. Although previous studies 
showed that ABC transporters are expressed at high 
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levels in these cells, the ability to pump out foreign 
chemicals is not the entire story when it comes to 
apoptotic resistance [8]. The current study [5], for 
example, shows that treatment with chemotherapeutics 
and radiotherapy is less effective at promoting apoptosis 
in CD44high cells, thereby arguing against a role for ABC 
transporters.
Increased apoptotic resistance is associated with a 
G2/M phase cell cycle block
What, then, is the reason behind the observed apoptotic 
insensitivity in CD44high CSCs? Insight into this question 
came from observations made by Mackenzie and 
colleagues [5], who showed that CD44high subpopulations 
of epithelial, breast and prostate carcinoma cells have a 
consistently higher proportion of cells in the G2 phase. 
Using pulse chase experiments involving 5-iodo-2’-
deoxyuridine (IdU) labeling of cells in S phase followed 
by FACS analysis, cell cycle progression was then tracked 
through G2 back into G1. The conclusion of this study is 
that CD44high cells spent a consistently longer time in G2.
In normal cell types, DNA damage caused by chemi-
cals, radiation or faulty replication halts cellular progres-
sion by activating a cell cycle checkpoint at the G2/M 
boundary, while DNA repair mechanisms restore 
genomic integrity. If the extent of damage is too great for 
repair mechanisms to correct, apoptosis is often induced 
[9]. Previous studies by Rich and colleagues [4] showed 
that glioblastoma cells are more resistant to radiotherapy 
than normal cells because they activate the DNA damage 
response. Checkpoint controls are implicated in this 
mecha nism because inhibition of Chk1 and Chk2 check-
point kinases remove the resistance to radiotherapy. A 
similar effect was observed by Mackenzie and colleagues 
[5], who found that levels of phosphorylated Chk1 and 
Chk2 are consistently higher in CD44high subpopulations 
and thus greater checkpoint activation is achieved. 
Knockdown of Chk1 and Chk2 by chemical inhibition or 
by small interfering RNA targeting in CD44high 
subpopulations led to a decrease in the percentage of 
cells in G2 phase to a level comparable to that of CD44low 
cells. This provides further confirmation for a mechanism 
in which CD44high CSCs, with a prolonged G2 phase, are 
apoptosis-resistant because of activated checkpoints. 
Activating checkpoint controls in CSCs therefore seems 
to impose a G2/M blockade, which gives a selective 
advantage in terms of cell survival and tumor-forming 
potential (Figure 1).
Future directions and therapeutic value
Mackenzie and colleagues [5] have revealed important 
additional information about the mechanisms by which 
tumors evade current therapeutic treatments. Of interest 
is the finding that CD44high subpopulations, displaying an 
Figure 1. Cancer stem cells (CSCs) escape apoptosis by upregulating G2/M checkpoint proteins, leading to a longer G2 phase and 
perhaps a longer window for DNA repair. Following chemo- or radiotherapy, all cells undergo DNA damage, but the extended G2 phase in CSCs 
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increase in apoptotic resistance and a longer G2 phase, 
were also found in normal oral keratinocytes. This 
observation is a strong argument for the idea that a small 
subpopulation of cells with inherent stem-like properties 
naturally occurs and is not solely a product of malignant 
transformation.
More importantly, the authors [5] demonstrate that in 
addition to the efficient efflux and DNA repair mecha-
nisms, CSCs also have an altered cell cycle program. 
Further biochemical characterization of these cells may 
explain how the G2/M checkpoint is activated and 
exactly how a longer G2 phase is conferring a survival 
advantage in cooperation with previously known mecha-
nisms. A key question is what signaling pathways activate 
checkpoints in CD44high cells. This could provide insight 
into what should be targeted for drug development. 
Prematurely releasing these cells from their prolonged 
G2 phase and G2/M block could trigger apoptosis instead 
of enhanced survival and tumor relapse. Therefore, it may 
be advantageous for future therapeutic treatments to 
target the Chk proteins or their upstream activators. In 
combination with modern chemical or radiation-based 
therapies, tumor elimination without relapse is an 
exciting possibility.
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